Merck celebrates another win in Januvia patent battle against Viatris

Viatris has suffered its second stinging loss in as many weeks in its attempt to challenge Merck’s Januvia and Janumet patents.

A federal appeals court on Thursday upheld Merck’s patent rights related to the dihydrogen phosphate salt of sitagliptin — an active ingredient in the blockbuster diabetes drugs Januvia, Janumet and extended-release formulation Janumet XR — calling Viatris’ claims “unpersuasive.”